A clinical trial in patients with cancer of the lung or the pancreas demonstrated that blockade of ACTRIIB using monoclonal antibody bimagrumab (BYM338) exerts an effect on preserving body weight and baseline of thigh muscle volume, total lean body mass, bone mineral density, and physical activity levels (NCT01433263). This evidence concerns the gene ACVR2B and cancer.